Research location
Garfield Heights
Ohio, United States
Advertisement
Research activity in Garfield Heights
Ohio, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 34 trials and 34 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Garfield Heights
34 linked trials · page 1 of 1Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsNCT06372964 · 2024-05-14 · 1 site observation
RECRUITING
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderNCT06229210 · 2024-01-25 · 1 site observation
RECRUITING
Safety and Tolerability of Open-Labeled Iloperidone in AdolescentsNCT05648591 · 2023-05-24 · 1 site observation
RECRUITING
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06029426 · 2023-09-20 · 1 site observation
COMPLETED
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic MedicationNCT05628103 · 2022-12-19 · 1 site observation
COMPLETED
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)NCT05518149 · 2022-09-22 · 1 site observation
TERMINATED
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive DisorderNCT05536414 · 2022-09-12 · 1 site observation
COMPLETED
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyNCT05455684 · 2022-06-22 · 1 site observation
COMPLETED
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05145413 · 2021-11-12 · 1 site observation
COMPLETED
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT04000009 · 2019-06-06 · 1 site observation
TERMINATED
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®NCT03892889 · 2019-04-29 · 1 site observation
TERMINATED
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT03968159 · 2019-04-25 · 1 site observation
COMPLETED
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaNCT03893825 · 2019-04-17 · 1 site observation
COMPLETED
Danger Signs in Heart Failure- Effects of Video EducationNCT03657459 · 2018-07-26 · 1 site observation
COMPLETED
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With SchizophreniaNCT03238326 · 2017-08-23 · 1 site observation
COMPLETED
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive DisorderNCT03002077 · 2017-02-03 · 1 site observation
COMPLETED
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive DisorderNCT02951988 · 2016-11-13 · 1 site observation
COMPLETED
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)NCT02943564 · 2016-11-01 · 1 site observation
COMPLETED
Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar DepressionNCT02600507 · 2016-03-07 · 1 site observation
COMPLETED
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar DepressionNCT02600494 · 2015-12-15 · 1 site observation
COMPLETED
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With SchizophreniaNCT02634320 · 2015-12-01 · 1 site observation
COMPLETED
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentNCT02153502 · 2014-07-01 · 1 site observation
COMPLETED
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive DisorderNCT01564862 · 2012-04-01 · 1 site observation
COMPLETED
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot AripiprazoleNCT01432444 · 2011-09-01 · 1 site observation
COMPLETED
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive DisorderNCT01114698 · 2011-03-01 · 1 site observation
TERMINATED
Safety and Efficacy of RX-10100 to Treat Major Depressive DisorderNCT01273376 · 2010-12-01 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)NCT01111565 · 2010-10-04 · 1 site observation
TERMINATED
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderNCT01179516 · 2010-08-01 · 1 site observation
COMPLETED
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive DisorderNCT00880048 · 2009-03-11 · 1 site observation
TERMINATED
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaNCT00731549 · 2008-12-01 · 1 site observation
COMPLETED
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaNCT00706654 · 2008-09-01 · 1 site observation
COMPLETED
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart FailureNCT00475852 · 2007-05-01 · 1 site observation
COMPLETED
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic FunctionNCT00094302 · 2006-08-01 · 1 site observation
COMPLETED
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialNCT00358215 · 2006-06-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.